Skip to content

Leo Pharma

Active
Public limited companyfounded 196759 yrs activeDuwijckstraat 17, 2500 Lier, BelgiumKBO/BCE: BE 0404.780.604
Summary

Leo Pharma has been active since 1967 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €9.9m and a net result of €615,360. Equity is growing by ~5.3% per year across the filed fiscal years. Its solvency ranks better than 72% of 5048 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Checked score

Score 2025
Axes · tick = 2024
Profitability59▼-2
Solvency91▼-9
Growth36▼-1
Track record100
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €750,000 at 30 days acceptable
Liquidity ample (current ratio 2.94 against 4.4 in 2024; short-term debt: 33.6% of total assets), and 34% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 59 years 0 60 y
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
66%
Return on assets
4.1%
Age of the figures
9 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Wholesale trade (NACE 46)
about 21% more bankruptcies
← fewer bankruptcies more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-05-2026, 86 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
86 d early
2024
38 d early
2023
71 d early
2022
56 d early
2021
3 d early
2020
8 d early
2019
18 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 40 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 5 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

Leo Pharma was incorporated on 1 April 1967.1 The registered office was moved to Lier in 2010.2 The board currently has 2 members; Hilda De Swaef has served longest, since 2012.3 Revenue grew from EUR 27 million in 2018 to EUR 32 million in 2025 and headcount from 30.9 to 21.7 full-time equivalents.4

  1. 1Crossroads Bank for Enterprises
  2. 2Belgian State Gazette, 25-05-2010
  3. 3Belgian State Gazette, 30-03-2022
  4. 4National Bank, annual accounts 2018 and 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

Turnover
€32.1m▼ 5.4%
2024 · €33.9m
EBIT margin
2.5%=
2024 · 2.5%
Net result
€615,360▼ 10.1%
2024 · €684,266
Working capital
€9.8m▲ 6.2%
2024 · €9.3m
Trend over the years

Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings. Dashed line: the median.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Turnover€27.2m▼ 2.8%€27.0m▼ 0.7%€33.1m▲ 22.7%€33.9m▲ 2.5%€32.1m▼ 5.4%
Operating result€664,563▼ 29.1%€84,902▼ 87.2%€974,049▲ 1,047%€845,935▼ 13.2%€798,745▼ 5.6%
Net result€413,203within the sector's middle half▼ 30.6%-€167,620below the sector's middle half€793,396above the sector's middle half€684,266above the sector's middle half▼ 13.8%€615,360above the sector's middle half▼ 10.1%
EBIT margin2.4%▼ 0.9pp0.3%▼ 2.1pp2.9%▲ 2.6pp2.5%▼ 0.5pp2.5%=
Equity€8.0mabove the sector's middle half▲ 5.4%€7.8mabove the sector's middle half▼ 2.1%€8.6mabove the sector's middle half▲ 10.1%€9.3mabove the sector's middle half▲ 7.9%€9.9mabove the sector's middle half▲ 6.6%
Total assets€20.7mabove the sector's middle half▼ 23.0%€19.1mabove the sector's middle half▼ 8.1%€17.5mabove the sector's middle half▼ 8.4%€12.1mwithin the sector's middle half▼ 30.5%€15.1mabove the sector's middle half▲ 23.9%
Debt€12.7m▼ 33.5%€11.2m▼ 11.8%€8.8m▼ 21.3%€2.8m▼ 68.0%€5.1m▲ 81.1%
Working capital€7.9mabove the sector's middle half▲ 0.9%€7.7mabove the sector's middle half▼ 1.6%€8.5mabove the sector's middle half▲ 10.5%€9.3mabove the sector's middle half▲ 8.5%€9.8mabove the sector's middle half▲ 6.2%
Solvency38.6%within the sector's middle half▲ 10.4pp41.1%within the sector's middle half▲ 2.5pp49.4%within the sector's middle half▲ 8.3pp76.7%above the sector's middle half▲ 27.3pp66.0%within the sector's middle half▼ 10.7pp
Current ratio1.62within the sector's middle half▲ 0.211.69within the sector's middle half▲ 0.071.97within the sector's middle half▲ 0.284.40above the sector's middle half▲ 2.432.94within the sector's middle half▼ 1.46
Return on assets (ROA)2.0%within the sector's middle half▼ 0.2pp-0.9%below the sector's middle half▼ 2.9pp4.5%within the sector's middle half▲ 5.4pp5.6%within the sector's middle half▲ 1.1pp4.1%within the sector's middle half▼ 1.5pp
Staff (FTE)33.1above the sector's middle half▲ 11.4%32.8above the sector's middle half▼ 0.9%26.8within the sector's middle half▼ 18.3%25within the sector's middle half▼ 6.7%21.7within the sector's middle half▼ 13.2%
above within below the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings.
Result per fiscal year
Operating resultNet result
-€500,000€0€500,000€1.0mOperating result 2021: €664,563€664,563Net result 2021: €413,203€413,203Operating result 2022: €84,902€84,902Net result 2022: -€167,620-€167,620Operating result 2023: €974,049€974,049Net result 2023: €793,396€793,396Operating result 2024: €845,935€845,935Net result 2024: €684,266€684,266Operating result 2025: €798,745€798,745Net result 2025: €615,360€615,36020212022202320242025€0€250,000€500,000€750,000€1mOperating result 2023: €974,049€974,000Net result 2023: €793,396€793,000Operating result 2024: €845,935€846,000Net result 2024: €684,266€684,000Operating result 2025: €798,745€799,000Net result 2025: €615,360€615,000202320242025
The operating result has fallen two years in a row; 2025 is 6% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €15.1m
Fixed assets €145,493 ▼ 4.2%
Current assets €14.9m ▲ 24.3%
Equity and liabilities €15.1m
Equity €9.9m ▲ 6.6%
Debt €5.1m ▲ 81.1%
Debt's share of the balance-sheet total rises from 23.3% to 34.0%. Equity and debt are higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€815,093▼
2024 · €867,000
Cash flow
€631,707▼
2024 · €705,331
Quick ratio
2.01▼
2024 · 2.20
Debt to equity
0.52▲
2024 · 0.30
ROE
6.2%▼
2024 · 7.3%
Interest coverage
1668.90▲
2024 · 93.76
Debt ≤ 1 year
€5.1m▲
2024 · €2.7m
Income taxes
€293,471▼
2024 · €312,740
Staff costs
€3.8m▼
2024 · €4.9m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 14,732 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 96% are still going.

  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet
0.2% went bankrupt
3.5% stopped otherwise
96% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 0.2% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,338 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.9%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 14,732 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 65 lines
Balance sheet Code20242025
Assets
Total assets20/58€12.1m€15.1m▲
Fixed assets21/28€151,853€145,493▼
Intangible fixed assets21€77,522€69,362▼
Tangible fixed assets22/27€34,861€36,662▲
Plant, machinery and equipment23€34,861€36,662▲
Financial fixed assets28€39,470€39,470=
Other financial fixed assets284/8€39,470€39,470=
Amounts receivable and cash guarantees285/8€39,470€39,470=
Current assets29/58€12.0m€14.9m▲
Stocks and contracts in progress3€6.0m€4.7m▼
Stocks30/36€6.0m€4.7m▼
Goods purchased for resale34€6.0m€4.7m▼
Amounts receivable within one year40/41€6.0m€10.1m▲
Trade receivables40€5.2m€5.0m▼
Other amounts receivable41€761,247€5.1m▲
Deferred charges and accrued income490/1-€80,000
Equity and liabilities
Total equity and liabilities10/49€12.1m€15.1m▲
Equity10/15€9.3m€9.9m▲
Contributions10/11€644,523€644,523=
Capital10€272,683€272,683=
Issued capital100€272,683€272,683=
Outside capital11€371,840€371,840=
Share premium1100/10€371,840€371,840=
Reserves13€27,268€27,268=
Non-distributable reserves130/1€27,268€27,268=
Legal reserve130€27,268€27,268=
Profit (loss) carried forward14€8.6m€9.3m▲
Amounts payable17/49€2.8m€5.1m▲
Amounts payable within one year42/48€2.7m€5.1m▲
Trade debts44€1.4m€4.1m▲
Suppliers440/4€1.4m€4.1m▲
Taxes, remuneration and social security45€1.3m€998,721▼
Taxes450/3€251,133€257,550▲
Remuneration and social security454/9€1.0m€741,171▼
Other amounts payable47/48€1,160€1,163▲
Accrued charges and deferred income492/3€101,818€55,486▼
Income statement Code20242025
Operating income70/76A€33.9m€32.3m▼
Turnover70€33.9m€32.1m▼
Other operating income74€9,859€256,163▲
Operating charges60/66A€33.1m€31.5m▼
Goods for resale, raw materials and consumables60€19.0m€18.7m▼
Purchases600/8€19.6m€17.4m▼
Change in stocks: decrease (increase)609-€577,789€1.3m▲
Services and other goods61€3.4m€3.5m▲
Remuneration, social security and pensions62€4.9m€3.8m▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€21,064€16,348▼
Other operating charges640/8€5.7m€5.5m▼
Operating profit (loss)9901€845,935€798,745▼
Financial income75/76B€160,318€115,470▼
Recurring financial income75€160,318€115,470▼
Income from current assets751€159,401€115,065▼
Other financial income752/9€918€404▼
Financial charges65/66B€9,247€5,384▼
Recurring financial charges65€9,247€5,384▼
Debt charges650-€488
Other financial charges652/9€9,247€4,895▼
Profit (loss) for the period before taxes9903€997,006€908,831▼
Income taxes67/77€312,740€293,471▼
Taxes670/3€312,740€293,471▼
Tax adjustments and reversals of tax provisions77€0-
Profit (loss) for the period9904€684,266€615,360▼
Profit (loss) for the period to be appropriated9905€684,266€615,360▼
Appropriation of the result
Profit (loss) to be appropriated9906€8.6m€9.3m▲
Profit (loss) brought forward from the previous period14P€8.0m€8.6m▲
Social balance
Average headcount (FTE)908725.021.7▼

The notes to these accounts (49 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Operating income70/76A€27.2m€29.0m€34.6m€33.9m€32.3m▼ 4.7%
Turnover70€27.2m€27.0m€33.1m€33.9m€32.1m▼ 5.4%
Other operating income74€0€2.0m€1.6m€9,859€256,163▲ 2,498%
Operating charges60/66A€26.5m€28.9m€33.7m€33.1m€31.5m▼ 4.7%
Goods for resale, raw materials and consumables60€17.4m€17.6m€21.9m€19.0m€18.7m▼ 1.8%
Purchases600/8€17.8m€17.7m€22.0m€19.6m€17.4m▼ 11.1%
Change in stocks: decrease (increase)609-€422,593-€83,931-€80,737-€577,789€1.3m▲ 317%
Services and other goods61€3.3m€4.3m€3.2m€3.4m€3.5m▲ 3.0%
Remuneration, social security and pensions62€4.4m€5.4m€4.9m€4.9m€3.8m▼ 23.1%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€44,919€50,357€32,746€21,064€16,348▼ 22.4%
Provisions for liabilities and charges: additions (uses and reversals)635/8-€200,000€0----
Other operating charges640/8€1.6m€1.6m€3.6m€5.7m€5.5m▼ 2.7%
Operating profit (loss)9901€664,563€84,902€974,049€845,935€798,745▼ 5.6%
Financial income75/76B€40,014€9,897€211,613€160,318€115,470▼ 28.0%
Recurring financial income75€40,014€9,897€211,613€160,318€115,470▼ 28.0%
Income from current assets751-€9,897€211,302€159,401€115,065▼ 27.8%
Other financial income752/9€40,014€0€312€918€404▼ 55.9%
Financial charges65/66B€3,873€15,021€4,535€9,247€5,384▼ 41.8%
Recurring financial charges65€3,873€15,021€4,535€9,247€5,384▼ 41.8%
Debt charges650€771€14,210€0-€488-
Other financial charges652/9€3,103€811€4,535€9,247€4,895▼ 47.1%
Profit (loss) for the period before taxes9903€700,704€79,777€1.2m€997,006€908,831▼ 8.8%
Income taxes67/77€287,501€247,398€387,732€312,740€293,471▼ 6.2%
Taxes670/3€287,501€282,009€387,732€312,740€293,471▼ 6.2%
Tax adjustments and reversals of tax provisions77-€34,612€0€0--
Profit (loss) for the period9904€413,203-€167,620€793,396€684,266€615,360▼ 10.1%
Profit (loss) for the period to be appropriated9905€413,203-€167,620€793,396€684,266€615,360▼ 10.1%
Line20212022202320242025Change
Assets
Total assets20/58€20.7m€19.1m€17.5m€12.1m€15.1m▲ 23.9%
Fixed assets21/28€228,994€178,636€145,890€151,853€145,493▼ 4.2%
Intangible fixed assets21€102,003€93,842€85,682€77,522€69,362▼ 10.5%
Tangible fixed assets22/27€87,521€45,324€20,738€34,861€36,662▲ 5.2%
Plant, machinery and equipment23€87,521€45,324€20,738€34,861€36,662▲ 5.2%
Other tangible fixed assets26€0-----
Financial fixed assets28€39,470€39,470€39,470€39,470€39,470=
Other financial fixed assets284/8€39,470€39,470€39,470€39,470€39,470=
Amounts receivable and cash guarantees285/8€39,470€39,470€39,470€39,470€39,470=
Current assets29/58€20.5m€18.9m€17.3m€12.0m€14.9m▲ 24.3%
Stocks and contracts in progress3€5.3m€5.3m€5.4m€6.0m€4.7m▼ 20.9%
Stocks30/36€5.3m€5.3m€5.4m€6.0m€4.7m▼ 20.9%
Goods purchased for resale34€5.3m€5.3m€5.4m€6.0m€4.7m▼ 20.9%
Amounts receivable within one year40/41€5.6m€13.6m€11.9m€6.0m€10.1m▲ 68.2%
Trade receivables40€5.1m€4.5m€4.5m€5.2m€5.0m▼ 5.1%
Other amounts receivable41€537,379€9.0m€7.4m€761,247€5.1m▲ 572%
Current investments50/53€9.6m€0----
Other investments51/53€9.6m€0----
Cash at bank and in hand54/58€2,870€0----
Deferred charges and accrued income490/1€0---€80,000-
Equity and liabilities
Total equity and liabilities10/49€20.7m€19.1m€17.5m€12.1m€15.1m▲ 23.9%
Equity10/15€8.0m€7.8m€8.6m€9.3m€9.9m▲ 6.6%
Contributions10/11€644,523€644,523€644,523€644,523€644,523=
Capital10€272,683€272,683€272,683€272,683€272,683=
Issued capital100€272,683€272,683€272,683€272,683€272,683=
Outside capital11€371,840€371,840€371,840€371,840€371,840=
Share premium1100/10€371,840€371,840€371,840€371,840€371,840=
Reserves13€27,268€27,268€27,268€27,268€27,268=
Non-distributable reserves130/1€27,268€27,268€27,268€27,268€27,268=
Legal reserve130€27,268€27,268€27,268€27,268€27,268=
Profit (loss) carried forward14€7.3m€7.2m€8.0m€8.6m€9.3m▲ 7.1%
Provisions and deferred taxes16€0-----
Provisions for liabilities and charges160/5€0-----
Other liabilities and charges164/5€0-----
Amounts payable17/49€12.7m€11.2m€8.8m€2.8m€5.1m▲ 81.1%
Amounts payable within one year42/48€12.7m€11.2m€8.8m€2.7m€5.1m▲ 85.8%
Trade debts44€11.5m€10.2m€7.6m€1.4m€4.1m▲ 184%
Suppliers440/4€11.5m€10.2m€7.6m€1.4m€4.1m▲ 184%
Taxes, remuneration and social security45€1.1m€914,948€1.2m€1.3m€998,721▼ 22.6%
Taxes450/3€440,892€123,077€417,492€251,133€257,550▲ 2.6%
Remuneration and social security454/9€668,452€791,870€760,548€1.0m€741,171▼ 28.7%
Other amounts payable47/48€0-€1,816€1,160€1,163▲ 0.3%
Accrued charges and deferred income492/3€77,971€67,199€51,211€101,818€55,486▼ 45.5%
Line20212022202320242025Change
Profit (loss) for the period9904€413,203-€167,620€793,396€684,266€615,360▼ 10.1%
+ Depreciation and write-downs630€44,919€50,357€32,746€21,064€16,348▼ 22.4%
Operating cash flow (approximation)€458,122-€117,263€826,142€705,331€631,707▼ 10.4%
Investment in fixed assets (approximation)-€0€0-€27,027-€9,988▲ 63.0%
Change in cash--€2,870----

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
09-06
State Gazette act Reappointment: DELOITTE Bedrijfsrevisoren (statutory auditor)
Permanent representative: Pieter-Jan Jean-Baptiste E Van Durme3 facts ▸
  • General meeting, 30-04-2026
  • Auditor reappointment, DELOITTE Bedrijfsrevisoren (statutory auditor)
  • Permanent representative, Pieter-Jan Jean-Baptiste E Van Durme (permanent vertegenwoordiger)
06-05
NBB filing Annual accounts filed
fiscal year 2025 · full schema
2025
23-06
NBB filing Annual accounts filed
fiscal year 2024 · full schema
15-04
State Gazette act Statutes amendment
Power of attorney4 facts ▸
  • General meeting, 11-04-2025
  • Statutes amendment
  • Power of attorney, Leo Pharma
  • Power of attorney, Leo Pharma
11-02
State Gazette act Appointment: Dilay Kücükkose (director)
Resignation: Anders Krüger (director) · Mandate compensation · Director discharge5 facts ▸
  • General meeting, 27-01-2025
  • Director appointment, Dilay Kücükkose (director)
  • Mandate compensation, Dilay Kücükkose
  • Director resignation, Anders Krüger (director)
  • Director discharge, Anders Krüger
30-01
State Gazette act Resignations & appointments
Power of attorney5 facts ▸
  • Board meeting, 20-01-2025
  • Power of attorney, Philip Van Den Eynden
  • Power of attorney, Mariana Vieira Falsca
  • Power of attorney, Martine Debecker
  • Power of attorney, Antoine Bodereau
2024
31-12
Financial Liquidity doublescurrent ratio 4.40
Current ratio from 1.97 to 4.40; short-term debt falls from €8.8m to €2.7m.
21-05
NBB filing Annual accounts filed
fiscal year 2023 · full schema
06-02
State Gazette act Resignation: Jannie Holm (director)
Appointment: Anders Krüger (director) · Mandate compensation6 facts ▸
  • General meeting, 10-01-2024
  • Director resignation, Jannie Holm (director)
  • Director appointment, Anders Krüger (director)
  • Mandate compensation, Anders Krüger
  • Board composition, Hilda De Swaef (director)
  • Board composition, Anders Krüger (director)
2023
31-12
Financial Back to profitnet €793,396
Net result €793,396 after one loss-making year.
28-06
State Gazette act Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Power of attorney5 facts ▸
  • Board meeting, 22-05-2023
  • Power of attorney, David Wilson
  • Power of attorney, Mariana Vieira Faísca
  • General meeting, 31-05-2023
  • Auditor reappointment, Deloitte Bedrijfsrevisoren BV
05-06
NBB filing Annual accounts filed
fiscal year 2022 · full schema
Show earlier events
2022
31-12
Financial Weakest financial yearnet -€167,620
Net result drops to -€167,620, the lowest in the series; recovery starts the following year.
02-09
State Gazette act Permanent representative: Pieter-Jan Van Durme
Accounting effect · Power of attorney4 facts ▸
  • Board meeting, 19-08-2022
  • Permanent representative, Pieter-Jan Van Durme
  • Accounting effect, 01-01-2021
  • Power of attorney, KPMG Law BV
08-08
State Gazette act Resignations & appointments
Power of attorney4 facts ▸
  • Board meeting, 15-07-2022
  • Power of attorney, Lucy Megens
  • Power of attorney, David Wilson
  • Power of attorney, Philip Van den Eynden
28-07
NBB filing Annual accounts filed
fiscal year 2021 · full schema
30-03
State Gazette act Resignation: Michael Grue (director)
Appointments: Jannie Holm (director) and Hilda De Swaef (director) · Director discharge · Mandate compensation11 facts ▸
  • General meeting, 17-03-2022
  • Director resignation, Michael Grue (director)
  • Director discharge, Michael Grue
  • Director appointment, Jannie Holm (director)
  • Director appointment, Hilda De Swaef (director)
  • Mandate compensation, Jannie Holm
  • Mandate compensation, Hilda De Swaef
  • Board composition, Jannie Holm (director)
  • Board composition, Hilda De Swaef (director)
  • Director appointment, Hilda De Swaef (managing director)
  • Governance structure, de Vennootschap opnieuw door een raad van bestuur zal worden bestuurd
05-01
State Gazette act Resignation: Catherine Mazzacco (director)
Director discharge · Statutes amendment · Power of attorney6 facts ▸
  • General meeting, 20-12-2021
  • Director resignation, Catherine Mazzacco (director)
  • Director discharge, Catherine Mazzacco
  • Board composition, Michael Grue (director)
  • Statutes amendment
  • Power of attorney, KPMG Law BV
2021
03-08
State Gazette act Reappointment: Deloitte Bedrijfsrevisoren CV (statutory auditor)
Permanent representative: Gert Vanhees · Resignations: Kim Kjøller (director) and Anders Kronborg (director) · Appointment: Michael Grue (director)10 facts ▸
  • General meeting, 30-06-2020
  • Auditor reappointment, Deloitte Bedrijfsrevisoren CV
  • Permanent representative, Gert Vanhees
  • General meeting, 06-07-2021
  • Director resignation, Kim Kjøller (director)
  • Director resignation, Anders Kronborg (director)
  • Director appointment, Michael Grue (director)
  • Mandate compensation, Michael Grue
  • Board composition, Michael Grue (director)
  • Board composition, Catherine Thérése Jeanne Mazzacco (director)
23-07
NBB filing Annual accounts filed
fiscal year 2020 · full schema
2020
25-11
State Gazette act Boekjaar
Purpose change · Statutes amendment · Capital7 facts ▸
  • General meeting, 20-10-2020
  • Purpose change, Uitbreiding van het voorwerp met: "De vennootschap heeft eveneens als voorwerp de controle van het bestuur of de deelneming aan het bestuur van elke onderneming…
  • Statutes amendment
  • Statutes amendment
  • Capital, €272.682,87
  • Statutes amendment
  • Governance, Bevestiging dat de vennootschap wordt bestuurd door een raad van bestuur; geen wijzigingen aan de mandaten.
29-09
State Gazette act Resignation: De Swaef (director)
Appointment: De Swaef (day-to-day manager) · Power of attorney8 facts ▸
  • General meeting, 18-08-2020
  • Board meeting, 18-08-2020
  • Director resignation, De Swaef (director)
  • Power of attorney, Michel Bonne
  • Power of attorney, Hannelore Matthys
  • Power of attorney, Andreas Wuylens
  • Power of attorney, Shaziea Habibi
  • Director appointment, De Swaef (day-to-day manager)
13-07
NBB filing Annual accounts filed
fiscal year 2019 · full schema
2019
29-11
NBB filing Annual accounts filed
fiscal year 2018 · full schema · 121 days late
31-10
State Gazette act Resignation: Aabo GITTE (director)
Appointment: Catherine Thérése Jeanne MAZZACCO (director) · Mandate compensation4 facts ▸
  • General meeting, 10-10-2019
  • Director resignation, Aabo GITTE (director)
  • Director appointment, Catherine Thérése Jeanne MAZZACCO (director)
  • Mandate compensation, Catherine Thérése Jeanne MAZZACCO
2018
28-09
NBB filing Annual accounts filed
fiscal year 2017 · full schema · 59 days late
27-08
State Gazette act Resignations & appointments · Miscellaneous
Management decision · Power of attorney · Mandate term4 facts ▸
  • Management decision, 08-08-2018
  • Power of attorney, Lucy Megens
  • Mandate term, onbepaalde duur
  • Mandate expiry condition, automatische vervaling wanneer mevrouw Megens niet langer werkzaam is voor de Vennootschap
03-01
State Gazette act Resignation: PricewaterhouseCoopers Bedrijfsrevisoren BCVBA (statutory auditor)
Appointment: Deloitte Bedrijfsrevisoren BCVBA (statutory auditor) · Mandate term4 facts ▸
  • General meeting, 30-10-2017
  • Auditor resignation, PricewaterhouseCoopers Bedrijfsrevisoren BCVBA (statutory auditor)
  • Auditor appointment, Deloitte Bedrijfsrevisoren BCVBA (statutory auditor)
  • Mandate term, until the general meeting approving the accounts for the fiscal year ending 31 December 2019
2017
27-04
NBB filing Annual accounts filed
fiscal year 2016 · full schema
2016
28-09
State Gazette act Resignation: Kristian Merser (director)
Appointment: Kim Kjøller (director)3 facts ▸
  • General meeting, 01-09-2016
  • Director resignation, Kristian Merser (director)
  • Director appointment, Kim Kjøller (director)
20-05
State Gazette act Reappointments: Gitte Aabo (director and chair of the board) and PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
Appointments: Kristian Merser (director) and Anders Kronborg (director) · Resignations: Lars Olsen, Lars Enghave Minor and Hilde De Swaef8 facts ▸
  • General meeting, 01-04-2016
  • Director reappointment, Gitte Aabo (director and chair of the board)
  • Director appointment, Kristian Merser (director)
  • Director appointment, Anders Kronborg (director)
  • Director resignation, Lars Olsen (director)
  • Director resignation, Lars Enghave Minor (director)
  • Director resignation, Hilde De Swaef (director)
  • Auditor reappointment, PricewaterhouseCoopers Bedrijfsrevisoren
2013
27-05
State Gazette act Reappointment: BCVBA PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
Permanent representative: Bart Vari Gompel3 facts ▸
  • General meeting, 11-04-2013
  • Auditor reappointment, BCVBA PricewaterhouseCoopers Bedrijfsrevisoren
  • Permanent representative, Bart Vari Gompel
2012
03-07
State Gazette act Resignations: Jens Bo Olesen (director) and Tore Waeborg (director)
Appointments: Lars Enghave Minor (director) and Hilda de Swaef (director) · Mandate compensation · Power of attorney19 facts ▸
  • General meeting, 15-06-2012
  • Director resignation, Jens Bo Olesen (director)
  • Director resignation, Tore Waeborg (director)
  • Director appointment, Lars Enghave Minor (director)
  • Director appointment, Hilda de Swaef (director)
  • Mandate compensation, Lars Enghave Minor
  • Mandate compensation, Hilda de Swaef
  • Board composition, Gitte Pugholm Aabo (director)
  • Board composition, Lars Olsen (director)
  • Board composition, Lars Enghave Minor (director)
  • Board composition, Hilda de Swaef (director)
  • Power of attorney, Tom Swinnen
  • +7 further facts in this act
2011
29-03
State Gazette act Capital & shares · Statutes amendment
Capital4 facts ▸
  • General meeting, 18-01-2011
  • Capital, €272.682,87
  • Statutes amendment
  • Board resolution, 25-02-2010
08-02
State Gazette act Resignation: BDO Bedrijfsrevisoren BCVBA (statutory auditor)
Appointment: PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor) · Mandate term4 facts ▸
  • General meeting, 27-09-2010
  • Director resignation, BDO Bedrijfsrevisoren BCVBA (statutory auditor)
  • Auditor appointment, PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
  • Mandate term, einde onmiddellijk na de gewone algemene vergadering van aandeelhouders te houden in 2013
2010
25-05
State Gazette act Registered office
Registered-office move2 facts ▸
  • Board meeting, 25-02-2010
  • Registered-office move, Duijckstraat 17, 2500 Lier
06-05
State Gazette act Appointments: Tore Waeborg, Hilde De Swaet and Lars Olsen
Reappointments: Gitte Aabo, Jens Bo Olesen and 2 others · Resignations: Ger Schoor (director) and Jens Bo Olesen (director)11 facts ▸
  • Board meeting, 25-02-2010
  • General meeting, 25-02-2010
  • Director appointment, Tore Waeborg (managing director)
  • Director appointment, Hilde De Swaet (director (executive))
  • Director reappointment, Gitte Aabo (director)
  • Director reappointment, Jens Bo Olesen (director)
  • Director reappointment, Tore Waeborg (director)
  • Director reappointment, Ger Schoor (director)
  • Director appointment, Lars Olsen (director)
  • Director resignation, Ger Schoor (director)
  • Director resignation, Jens Bo Olesen (director)
2008
30-12
State Gazette act Resignation: Ernst Lunding (director)
Reappointments: Gitte Aabo, Bo Olesen and 3 others · Permanent representative: Jan Vercauteren · Mandate compensation9 facts ▸
  • General meeting, 04-03-2008
  • Director resignation, Ernst Lunding (director)
  • Director reappointment, Gitte Aabo (director)
  • Director reappointment, Bo Olesen (director)
  • Director reappointment, Ger Schoor (director)
  • Director reappointment, Tore Waeborg (director)
  • Mandate compensation, LEO PHARMA
  • Auditor reappointment, BDO Bedrijfsrevisoren
  • Permanent representative, Jan Vercauteren (company auditor)
04-02
State Gazette act Reappointments: Ernst Lunding, Jens Bo Olesen and Ger Schoor
Appointments: Gitte Aabo (director) and Tore Waeborg (director) · Mandate term · Number of directors12 facts ▸
  • General meeting, 06-03-2007
  • Director reappointment, Ernst Lunding (director)
  • Director reappointment, Jens Bo Olesen (director)
  • Director reappointment, Ger Schoor (director)
  • Director appointment, Gitte Aabo (director)
  • Director appointment, Tore Waeborg (director)
  • Mandate term, eindigt onmiddellijk na de jaarvergadering die zal worden gehouden in 2008
  • Mandate term, eindigt onmiddellijk na de jaarvergadering die zal worden gehouden in 2008
  • Mandate term, eindigt onmiddellijk na de jaarvergadering die zal worden gehouden in 2008
  • Mandate term, eindigt onmiddellijk na de jaarvergadering die zal worden gehouden in 2008
  • Mandate term, eindigt onmiddellijk na de jaarvergadering die zal worden gehouden in 2008
  • Number of directors, 5
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
26 of 26 acts read

Directors · office · real estate

Directors
2 directors, 1 in day-to-day management, no change since 2025

Board 2

Hilda De Swaef
Director · since 01-07-2012
Current
Dilay Kücükkose
Director · since 27-01-2025
Current
3 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Catherine Thérése Jeanne MAZZACCO
Director · since 10-10-2019
Not recently confirmed
Bo Olesen
Director
Not recently confirmed
Not recently confirmed

Day-to-day management 1

Hilda De Swaef
Managing director · since 01-07-2012
Current

Statutory auditor 1

Deloitte Bedrijfsrevisoren
Statutory auditor · since 01-11-2017 · perm. rep.: Pieter-Jan Jean-Baptiste E Van Durme
Current

Other functions 1

Hilde De Swaet
Director (executive) · since 25-02-2010
Not recently confirmed
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →
Location & real-estate footprint
Registered office, Lier · 1 establishment unit since 1971
seat establishment The establishment unit on the map
Ground area
5.6 ha
Building footprint
2.3 ha
Volume, LiDAR
252,228 m³
Parcel 12392A0300/00C000, Flanders · tallest building 20.8 m, ±3 floors. Linked by address, not a title deed.
68 companies at this address See who is registered here
1 establishment unit
Leo Pharma
Duwijckstraat 17, 2500 LierManufacture of basic metals
since 19712.039.452.516
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
12392A0300/00C000 Flanders 5.6 ha 1 · 2.3 ha 20.8 m · 3 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Mandate history

24 people since 2007, 7 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • Other function
  • not recently confirmed
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Hilda De Swaef
  • Director, from 01-07-2012 to date
  • Managing director, from 01-07-2012 to date
Dilay Kücükkose
  • Director, from 27-01-2025 to date
Deloitte Bedrijfsrevisoren
  • Statutory auditor, from 01-11-2017 to date
Ernst Lunding
  • Director, until 01-01-2008
  • Director, already before 04-02-2008 not ended, last confirmed 04-02-2008
Bo Olesen
  • Director, already before 30-12-2008 not ended, last confirmed 30-12-2008
Catherine Thérése Jeanne MAZZACCO
  • Director, from 10-10-2019 not ended, last confirmed 31-10-2019
Hilde De Swaet
  • Director (executive), from 25-02-2010 not ended, last confirmed 06-05-2010
Anders Krüger
  • Director, from 31-01-2024 to 27-01-2025
Jannie Holm
  • Director, from 31-03-2022 to 31-01-2024
Michael Grue
  • Director, from 31-12-2020 to 31-03-2022
Catherine Mazzacco
  • Director, until 30-11-2021
De Swaef
  • Day-to-day manager, from 25-02-2010 ended, last mentioned 29-09-2020
  • Director, until 01-04-2016
Anders Kronborg
  • Director, from 01-04-2016 to 30-06-2020
Kim Kjøller
  • Director, from 01-09-2016 to 30-06-2020
Aabo GITTE
  • Director, from 06-03-2007 to 10-10-2019
PricewaterhouseCoopers, Bedrijfsrevisoren
  • Auditor, from 27-09-2010 to 01-11-2017
Kristian Merser
  • Director, from 01-04-2016 to 01-09-2016
Hilde De Swaef
  • Director, until 01-04-2016
Lars Enghave Minor
  • Director, from 01-07-2012 to 01-04-2016
Lars Olsen
  • Director, from 01-03-2010 to 01-04-2016
Jens Bo Olesen
  • Director, already before 04-02-2008 to 01-03-2010
  • Director, until 01-07-2012
Tore Waeborg
  • Director, from 06-03-2007 to 01-07-2012
  • Managing director, from 25-02-2010 to 01-07-2012
BDO Bedrijfsrevisoren
  • Auditor, from 04-03-2008 to 27-09-2010
Ger Schoor
  • Director, already before 04-02-2008 to 01-03-2010
See the board, name and seat on a given date →

Articles of association

Purpose
De fabricage, de import en export, alsmede de handel, de makelarij en de commissieverhandeling, zo in het groot als in het half groot en in het klein, van alle farmaceutische…
Full purpose

De fabricage, de import en export, alsmede de handel, de makelarij en de commissieverhandeling, zo in het groot als in het half groot en in het klein, van alle farmaceutische producten, de exploitatie van octrooien, merken en licenties, research op wetenschappelijk en op economisch vlak en op marktgebied in verband daarmede, dit alles rechtstreeks en zijdelings, door financiering van andere bedrijven en het nemen van belangen in deze ondernemingen. De vennootschap zal eveneens alle onroerende goederen kunnen huren en verhuren, in concessie en erfpacht mogen geven en nemen. De vennootschap heeft eveneens als voorwerp de controle van het bestuur of de deelneming aan het bestuur van elke onderneming, in voorkomend geval door het uitoefenen van een mandaat, zoals dit van bestuurder, lid van de raad van toezicht of de directieraad. Zij kan ook het mandaat van vereffenaar uitoefenen. De vennootschap kan alle financieringen, zoals leningen, kredieten of gelijkaardige verrichtingen, aangaan en toestaan. De vennootschap kan zekerheden verstrekken, zowel voor haar eigen verbintenissen als voor de verbintenissen van andere groepsvennootschappen, onder andere door haar goederen in hypotheek of in pand te geven, met inbegrip van haar handelsfonds. De vennootschap zal in het algemeen alle commerciële, industriële, financiële, roerende en onroerende handelingen mogen verrichten in rechtstreeks of onrechtstreeks verband met haar voorwerp of die van aard zouden zijn dat zij het bereiken ervan geheel of ten dele vergemakkelijken.

Structure & network

Connections & network

2 current directors
Depth

The network starts from this company’s directors. Other companies they run appear here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.

Capital and shareholders

Capital over the years
  1. 25-11-2020 Capital stated in 2 acts · 272,682.87 EUR · 55,992 shares

Similar companies · same sector, comparable size

Of 1,903 companies in sector 46460 we hold annual accounts for 1,126. 447 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded01-04-1967
Fiscal year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
Contact
E-mail leo-pharma.be@leo-pharma.com
Phone +3237407868
Fax +3237407869
E-invoicing
Reachable via Peppol
Peppol ID 0208:0404780604
Registered 15-12-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.